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Metabolomic and Lipidomic 
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Endometrial cancer (EC) remains the most common malignancy of the genital tract among women in 
developed countries. Although much research has been performed at genomic, transcriptomic and 
proteomic level, there is still a significant gap in the metabolomic studies of EC. In order to gain insights 
into altered metabolic pathways in the onset and progression of EC carcinogenesis, we used high 
resolution mass spectrometry to characterize the metabolomic and lipidomic profile of 39 human EC 
and 17 healthy endometrial tissue samples. Several pathways including lipids, Kynurenine pathway, 
endocannabinoids signaling pathway and the RNA editing pathway were found to be dysregulated in 
EC. The dysregulation of the RNA editing pathway was further investigated in an independent set of 
183 human EC tissues and matched controls, using orthogonal approaches. We found that ADAR2 is 
overexpressed in EC and that the increase in expression positively correlates with the aggressiveness of 
the tumor. Furthermore, silencing of ADAR2 in three EC cell lines resulted in a decreased proliferation 
rate, increased apoptosis, and reduced migration capabilities in vitro. Taken together, our results 
suggest that ADAR2 functions as an oncogene in endometrial carcinogenesis and could be a potential 
target for improving EC treatment strategies.
Endometrial cancer (EC) accounts for 7% of the new cases of female cancers in United States in 2017 and its inci-
dence is increasing1, 2. The most standardized classification divides EC in two different subtypes: type I or endo-
metrioid carcinomas (EEC), which is the most frequent subtype; and type II or non-endometrioid carcinomas 
(NEEC), which are more aggressive tumors. Among NEEC subtypes, serous is the most prominent histology3, 4. 
Moreover, EC tumors are classified according to the extent of tumor dissemination (International Federation 
of Gynecology and Obstetrics or FIGO staging) and histological grade1. About 20% of patients are diagnosed at 
an advanced stage and/or at a high histological tumor grade and have a low 5-year survival rate associated5, 6. As 
such, availability of biomarkers for disease stratification and a thorough understanding of biochemical perturba-
tions that underscore EC progression are likely to improve clinical outcomes.
Extensive research performed using high-throughput technologies including genomics, transcriptomics and 
proteomics has augmented characterization of molecular changes at different levels of cellular expression that are 
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specifically associated with human endometrium7 and onset and progression of EC8, 9. Metabolomics defines the 
end point of cellular processes and hence provides a readout of current physiological status of the system10. Thus, 
metabolomics, lipidomics and glycomics have emerged as promising tools for clinical and translational research11. 
Rapid advancement of metabolomics technologies such as ultra-performance liquid chromatography mass 
spectrometry (UPLC-MS), enable comprehensive interrogation of the human metabolome and lipidome12–15. 
Bioinformatics analyses of these data is likely to augment the discovery of new clinical and pharmacological 
targets16.
It is known that changes at the transcriptomic levels generate a new source of complexity that promotes ini-
tiation and progression of cancer and other diseases17–19. The most common RNA editing events are mediated 
post-transcriptionally by the Adenosine deaminases acting on RNA (ADAR) family of enzymes20. The ADAR 
gene family catalyzes the deamination of adenosine that is converted to an inosine creating a dysregulation of the 
adenosine/inosine (A/I) ratio in the cell. Adenosine to inosine (A-to-I) editing can lead to amino acid recoding 
events21 since inosine is recognized as a guanosine. This family includes three enzymes, ADAR1 (UniProtKB 
P55265), ADAR2 (UniProtKB P78563) and ADAR3 (UniProtKB Q9NS39); also known as ADAR, ADARB1 and 
ADARB2, respectively22. ADAR1 and ADAR2 are ubiquitously expressed and, differently that the brain specific 
ADAR3, they show catalytic activity23.
The overall goal of this study was to identify altered metabolic pathways in EC. Characterization of the metab-
olome and lipidome of EC tumors was performed using a high resolution mass spectrometry approach in con-
junction with UPLC-MS. Pathway validation was performed with an independent set of samples that for the first 
time, yielded insights into dysregulation of the RNA editing pathway in endometrial tumors. Alterations of the 
RNA editing pathway correlated with high histological grade and EC serous subtypes that are indicators of poor 
prognosis in EC. Finally, the expression of ADAR editing enzymes was modulated in vitro to confirm an impor-
tant oncogenic role of this pathway in EC cell proliferation, apoptosis and migration. These results are instructive 
of the role of this pathway in EC tumor progression.
Results
Untargeted metabolomics profiling of EC human tissue samples. To better understand alterations 
in metabolic pathways occurring in EC, we performed metabolomics/lipidomics untargeted discovery using 
UPLC-ESI-TOF-MS of tumor and non-tumoral tissue samples. The sample set included a total of 56 samples: 39 
EEC tumors from different FIGO stages, including 10 stages IA, 9 stages IB, 10 stages II and 10 stages III; and 17 
benign endometrial tissues (see patient details in Table 1). All patients included in the study were postmenopausal 
women and did not receive any treatment before surgery. Pre-processing of TOFMS data yielded a total of 8,146 
features in the positive and 7,558 in the negative electrospray ionization mode, respectively.
In order to define a generic metabolomic profile of EC, initially, we combined all tumor samples from EEC 
patients in one group (n = 39) and compared them against matched control tissues (n = 17). Inherent differences 
in metabolomic profiles were visualized using descriptive Principal Component Analysis (PCA) plot that showed 
clear separation between tumors and controls (Fig. 1A). Subsequently, t-statistics was used to select 80 metabo-
lites that showed significant variation (adjusted p-value < 0.05) between the two study groups and fold change 
(FC) values over 2 and below 0.5 (Supplementary Table 1). We confirmed the putative identity of a subset of 42 
metabolites using tandem mass spectrometry (MS/MS) (Table 2). An example of the fragmentation pattern of 
two verified metabolites is shown in Supplementary Figures 1 and 2. We found a significant dysregulation in the 
lipid metabolism, with an important number of glycerophosphocholines (PCs), phosphatidylserine (PSs), phos-
phatidylethanolamines (PEs), phosphatidylinositols (PIs), and phosphatidylglycerol (PGs) that were upregulated 
in the endometrial tumor tissue (detailed in Table 2) including PC (14:0/18:2), PC (16:0/20:4), PC (16:0/20:5), 
PC (16:0/22:6), PC (18:0/20:2), PC (18:1/14:0), and PC (18:1/22:6). Moreover, a total of 9 PEs (PE (16:0/22:6), PE 
(16:1/P-18:1), PE (18:0/0:0), PE (18:0/18:3), PE (18:1/22:6), PE (18:1/16:0), PE (18:1/18:1), PE (18:4/P-18:1) and 
PE (P-16:0/0:0)) and 4 PIs (PI (14:0/22:1), PI (16:0/18:1), PI (16:0/22:3) and PI (18:1/18:1)) showed significant 
changes in the relative abundance in EC tumors as compared to the matched controls. Metabolites such as linoleic 
acid, 3-Deoxyvitamin D3, UDP-N-acetyl-D-galactosamine and 1-Palmitoyl-2-linoleoyl PE were observed to be 
also upregulated whereas peptide Glu Phe Arg Trp, some amides (palmic amide, stearamide and oleamide), PA 
(18:0/18:1), PE (20:1/22:6), PE (22:6/P-18:1), PG (19:0/22:4) and other important metabolites such inosine and 
picolinic acid showed lower abundance in the tumor tissue.
Few studies have used high-throughput approaches to study the changes in metabolomic and lipidomic pro-
files that underscore EC progression. Hence, in order to understand the metabolic phenotype associated with EC 
development, we interrogated profile differences in 29 tumor tissues restricted to the uterine cavity (FIGO stages I 
and II) compared to 10 tumors showing lymph node dissemination (FIGO stage III). We found a set of features to 
be significantly dysregulated (adjusted p-value < 0.05) among the different FIGO stages (Supplementary Table 2). 
Diagnosis Number of samples FIGO stage Type I/II Pre/Postmenopausal Phase
Control tissue 17 Post Discovery and verification
EC tissue
10 IA I Post Discovery and verification
9 IB I Post Discovery and verification
10 II I Post Discovery and verification
10 III I Post Discovery and verification
Table 1. Clinical and histopathological information of the patients included in this study.
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The PCA plots showing the segregation of the groups and the heat map showing the expression of several features 
in normal endometrium and in different FIGO stages of the tumor are represented in Fig. 1B and C. A subset of 
seven metabolites was verified by MS/MS (Table 3). The dysregulation observed in lipids (two PCs and three PEs) 
in tumor tissues compared to controls was significant along tumor progression. Additionally, we observed that 
arachidonic acid and UDP-N-acetyl-D-galactosamine are important contributors in the tumor progression, as 
they appeared to be upregulated in advanced compared to early FIGO stages (Supplementary Figure 3).
Increased expression of ADAR family of enzymes in human EC tumors. Among the metabolites 
identified in EC tissues, we were particularly interested in the dysregulation of nucleoside inosine since the rela-
tive abundance of this metabolite was significantly higher in EC tumors. To our knowledge, the underlying impact 
of alterations of endogenous levels of inosine has never been investigated in EC. Dysregulated levels of adeno-
sine and inosine (A/I ratio) can be attributed to the modulation of the A-to-I editing pathway24. Consequently, 
we studied the status of this pathway in EC by analyzing the expression level of members of the A-to-I editing 
enzymes family (ADAR1 and ADAR2) in three independent sets of samples by immunohistochemistry (IHQ) 
(Table 4). The first set included the evaluation of 20 EEC samples and their corresponding paired healthy tissues; 
the second set included 36 EEC tumors diagnosed at different histological grades (low grade, n = 12; intermediate 
grade, n = 13; high grade, n = 11); and the third set allowed to differentiate between histological subtypes, and so, 
78 EEC and 29 NEEC tissue samples were included.
Although ADAR1 and ADAR2 staining was clearly localized in the nucleus of epithelial, stromal, and 
endothelial cells, we specifically analyzed the staining of the epithelial tumor cells (Fig. 2B,D,F and Supplementary 
Figure 4B). Interestingly, no staining was observed in cells undergoing mitosis (Supplementary Figure 4A). Our 
results demonstrated that ADAR1 and ADAR2 were both significantly increased in tumor samples compared to 
healthy endometrial tissue (Fig. 2A), confirming that the RNA editing pathway is activated in EC carcinogenesis. 
ROC analysis for ADAR1 and ADAR2 expression yielded an AUC of 0.79 and 0.90 respectively, emphasizing the 
differences observed between control and EC samples (Supplementary Figure 5). Moreover, ADAR expression 
increased progressively with the presence of poor prognostic factors, such as tumors presenting high grade or a 
NEEC histology (Fig. 2C and E). These data suggested for the first time an activation of the RNA editing pathway 
in patients with EC, which positively correlates with aggressive disease, resulting in a dysregulation of the nucle-
osides/nucleotides balance in the tumor tissue.
Inhibition of ADAR2 reduces viability, increases apoptosis and reduces migration capabilities 
in human EC cell lines. Next, in order to determine the possible role of the RNA editing pathway in EC 
Figure 1. Multivariate analysis showing metabolic profiles in EC. Principal Component Analysis (PCA) plots 
showing separation between EC tissue samples (T, in green) and control tissue samples (N, in red) (Panel A) and 
separation between different EC FIGO stages (stage 1: TI, stage 2: TII, stage 3: TIII) (Panel B) for the positive 
MS ionization mode. X-axis shows interclass separation and Y-axis illustrates the intra-class variability. Panel C. 
Heat map of ion rankings, corresponding to their relative concentrations (intensity) for positive MS ionization 
mode, in the same cohort of subjects. Each row represents a unique feature with a specific m/z and RT while 
each column represents a unique subject. (m/z: mass to charge ratio; RT: retention time).
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Picolinic acid 122.02446 2 0.6499 ↓ 0.1834 3.07E-03 3.47E-03 0.8275 C6H5NO2 Negative 107.01, 105.02, 87.12, 81.53
Linoleic acid 279.2320 3 6.9054 ↑ 3.2817 2.33E-02 2.33E-02 0.6772 C18H32O2 Negative 240.99, 170.99, 96.96
Vaccenic acid 281.2482 1 7.3972 ↓ 0.12817 1.65E-07 4.73E-07 0.6352 C18H34O2 Negative 94.99, 96.96, 100.99, 126.90
Arachidonic Acid (peroxide free) 303.2325 1 6.8246 ↓ 0.29314 9,94E-04 1.30E-03 0.6439 C20H32O2 Negative 259.25, 216.99, 205.19




PE(P-16:0/0:0) 436.2827 1 5.8143 ↑ 8.4545 1.82E-03 2.24E-03 0.7984 C21H44NO6P Negative 78.96, 140.01, 196.03
PE(18:0/0:0) 480.3092 0 6.3049 ↑ 11.4850 7.95E-04 1.07E-03 0.8246 C23H48NO7P Negative 96.96, 140.01, 196.04, 283.27
PG(22:6/0:0) 555.2716 2 5.6562 ↑ 5.2860 4.68E-03 5.16E-03 0.8024 C28H45O9P Negative 170.98, 283.24, 327.23





PE(16:1/P-18:1) 698.5116 2 9.5703 ↑ 2.9631 9.80E-03 1.05E-02 0.7232 C39H74NO7P Negative 78.96, 140.00, 253.21, 281.23
PA (18:0/18:1) 701.5236 0 9.8145 ↓ 0.1377 3.47E-06 7.85E-06 0.9056 C38H75N2O7P Negative 281.25, 283.25, 419.25, 437.28
1-Palmitoyl-2-linoleoyl PE 714.5078 0 9.4018 ↑ 14.4588 1.16E-04 1.92E-04 0.8549 C39H74NO8P Negative 140.01, 255.23, 279.22
PE(18:1/16:0) 716.5231 0 9.2768 ↑ 20.1049 6.31E-04 8.75E-04 0.8491 C39H76NO8P Negative 140.01, 196.04, 281.25
PE(18:4/P-18:1) 720.4964 1 9.8168 ↑ 12.3568 1.50E-04 2.39E-04 0.859 C41H72NO7P Negative 259.20, 581.49
PE(18:0/18:3) 740.5213 3 9.4586 ↑ 2.4862 8.10E-07 2.18E-06 0.8823 C41H76NO8P Negative 140.01, 283.24, 482.32
PE(18:1/18:1) 742.5388 0 9.4276 ↑ 86.8130 2.11E-06 5.04E-06 0.9324 C41H78NO8P Negative 140.01, 281.24, 460.28, 478.30
PG(O-16:0/20:1) 761.5677 3 9.1881 ↑ 2.4041 3.40E-04 5.04E-04 0.8392 C42H83O9P Negative 152.99, 255.23, 391.20, 465.25








PS(13:0/22:1) 774.5303 1 8.9030 ↑ 76.5521 2.09E-09 1.12E-08 0.9307 C41H78NO10P Negative 152.99, 491.31, 687.49














PG(19:0/22:4) 839.5768 4 9.8027 ↓ 0.4242 4.47E-06 9.15E-06 0.8753 C47H85O10P Negative 78.95, 152.99, 331.26




PI(14:0/22:1) 863.5645 1 9.8451 ↑ 60.5400 8.37E-08 2.88E-07 0.9161 C45H85O13P Negative 78.96, 152.99, 241.01
PI(16:0/22:3) 887.5644 1 8.3686 ↑ 56.9735 6.90E-13 9.89E-12 0.7633 C47H85O13P Negative 78.95, 152.99, 241.01, 553.24
Inosine 267.07301 1 0.4075 ↓ 0.1724 2.68E-03 3.11E-03 0.7984 C10H12N4O5 Negative 135.03, 108.02, 92.03
Continued
www.nature.com/scientificreports/
5SCIENtIfIC RepoRts | 7: 8803  | DOI:10.1038/s41598-017-09169-2
progression, we transiently silenced the expression of the ADAR1 and ADAR2 enzymes in three EC cell lines 
(HEC-1A, Ishikawa and RL95-2). Transfection efficiency was determined by comparing each transfection against 
the corresponding negative control (NC) (Supplementary Figure 6). Gene silencing for both enzymes was con-
firmed by western blot analysis (WB) and immunofluorescence (IF) after 96 h of transfection (Supplementary 
Figure 7), time point in which the modulation of cell growth and cell viability in EC cell lines was assessed. 
The inhibition of ADAR2, but not ADAR1, resulted in a significant reduction of cell viability and proliferation 
compared to controls in the three cell lines used in this study (Fig. 3A). Furthermore, the ratio of apoptotic cells 
significantly increased in the three cell lines upon silencing of ADAR2. Similarly, proliferation assay performed 
using cells treated with siRNA-ADAR1, did not result in significant changes in apoptosis (Fig. 3B). Finally, the 
migration capabilities of the EC cell lines were interrogated after inhibiting ADAR1 and ADAR2 in a wound heal-
ing assay. Knockdown of ADAR2 expression resulted in significant reduction of the migration rate in HEC-1A 
























































PC(14:0/18:2) 730.5416 4 8.9420 ↑ 286.1312 9.26E-10 5.69E-09 0.9312 C40H76NO8P Positive 184.07, 242.11, 285.24
PC(18:1/14:0) 732.5552 1 7.6818 ↑ 4.9261 2.68E-12 2.53E-11 0.8275 C40H78NO8P Positive 86.09, 184.07, 549.48
PC(16:0/20:5) 780.5545 0 8.8476 ↑ 40.7199 6.95E-08 2.72E-07 0.9161 C44H78NO8P Positive 88.11, 184.07, 255.21, 393.24












PC(18:0/20:2) 814.6337 2 9.9895 ↑ 10.9063 3.56E-04 5.10E-04 0.7925 C46H88NO8P Positive 184.07, 263.27, 341.30, 508.37
PC(18:1/22:6) 832.5861 1 9.8159 ↑ 9.9810 8.71E-08 2.88E-07 0.8922 C48H82NO8P Positive 184.07, 522,35, 568,33
Table 2. Potential biomarkers confirmed by MS/MS. The table lists metabolites that showed significant change 
in the relative abundance in EC tissues compared to controls. (m/z = mass/charge; ppm = parts per million; 
RT = retention time; p-v = p-value; FC = fold change; FDR = false discovery rate; AUC = area under the curve).
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In order to further confirm the functional role of ADAR2 in EC cell lines, we also conducted functional assays 
silencing ADAR2 expression with two new and different siRNAs (siRNA-ADAR2_B and siRNA-ADAR2_C), 
independent from the siRNA-ADAR2 used in Fig. 3. We corroborate a significant decrease of cell viability, a sig-
nificant increase in apoptosis rate and a significant decrease of wound healing rate of the 3 EC cell lines induced 
by the silencing of ADAR2 expression (Supplementary Figure 8). These results clearly demonstrate that changes 
in the expression of ADAR2 leads to significant changes in the aggressive behavior of EC cell lines, specifically on 
cell viability and apoptosis, and cell migration capabilities of EC cell lines.
Discussion
Recently, few studies have reported alterations in the metabolomic or proteomic phenotype of EC in serum25, 
urine26 or in other sample types27, 28, underscoring the clinical translational relevance of these technologies in 
furthering the personalized medicine initiative. In this study, we used a global metabolomics profiling approach 
in order to understand the metabolic changes that take place in EC carcinogenesis and during tumor progression 
(Fig. 4).
Our study reveals an array of metabolites dysregulated in EC, some of which have been previously described 
in endometrial carcinogenesis. Glycerophospholipid class of metabolites was found to be upregulated in tumor 
tissues, including PCs, PEs, and PIs. Lipid biosynthesis and catabolism is known to be altered in several diseases, 
including cancer28–32. Consistent with our findings, Trousil et al.28 also observed an increase (up to 70%) in PC 
levels in EC tissues. We also observed a downregulation of the acylamido analogs of endocannabinoids such 
as palmitamide, stearamide and oleamide in EC. This downregulation has been previously reported33. We also 
observed a decreased proportion of picolinic acid in tumor samples. Picolinic acid and quinolinic acid are the 
end products of the Kynurenine pathway and have been shown to have anti-tumoral and pro-tumoral activity 
respectively34. Moreover, the activity of one of the main enzymes of the pathway, indoleamine 2,3-dioxygenase 
(IDO) has also been studied in EC35. Decreased levels of Glu Phe Arg Trp and inosine as well as upregulation 
of 3-Deoxyvitamin D3 and UDP-N-acetyl-D-galactosamine were also found in our EC tumor sample set com-
pared to control tissues. We also analyzed metabolomic changes that underscore tumor progression. Our data 
suggest significant changes in the lipidome including PC (16:0/20:5), PC (16:0/22:6), PE (16:0/22:6), PE (22:6/P-






























































Table 3. Potential biomarkers confirmed using tandem mass spectrometry. List of metabolites that showed 
significant alterations in early vs late stages of EC. (m/z = mass/charge; ppm = parts per million; RT = retention 
time; p-v = p-value; FC = fold change; FDR = false discovery rate; AUC = area under the curve).
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UDP-N-acetyl-D-galactosamine and arachidonic acid at advanced stages of EC. Further studies would be needed 
to fully understand the scope and impact of these alterations in cancer progression.
The dysregulation of inosine was further studied to dissect the functional implications of the RNA editing 
pathway in EC. The dysregulation of inosine is indicative of a possible imbalance in the I/A ratio, which was also 
reported by Trousil et al.28 in studies with EC tissue compared to normal endometrium. The A-to-I conversion is 
the most common type of RNA editing found in mammals mediated by the ADAR enzymes. Although, to date, 
the RNA editing pathway and the expression and function of the ADAR gene family has not been interrogated 
in EC, it has been reported that the expression of ADAR enzymes is upregulated in many cancers18, 19, including 
breast17 and esophageal squamous cell carcinoma36, 37. The ADAR family is comprised of three members: ADAR1 
and ADAR2, that are present in most human tissues; and ADAR3, that is brain specific23. Changes in editing fre-
quencies have been described in other diseases including prostate, lung, kidney and testis tumors while reduced 
RNA levels of ADAR1, ADAR2 and ADAR3 have been observed in brain tumors38, 39. ADAR enzymes are also 
involved in physiological events such neuronal development, immune response, cell response to viruses and reg-
ulation of miRNA expression among others40, 41.
Hence, we asked if the expression of ADAR enzymes had any correlation with EC initiation and progression. 
Our findings not only elucidate ADAR1 and ADAR2 enzymes to be significantly upregulated in EC tumor tissues 
compared to healthy endometrium, but also demonstrate a significant correlation between ADARs expression 
and the malignancy of the tumor. We found that the ADARs expression increased progressively with tumor grade. 
More importantly, our data showed a significant increase in the expression of ADAR1 and ADAR2 in the most 
aggressive subtype of EC, the NEEC, that have the worst predicted survival3.
The role of the RNA editing pathway in EC was further investigated by knocking-down the expression of 
ADAR1 and ADAR2 in HEC-1A, RL95-2 and Ishikawa EC lines. Our results demonstrate the impact of decreased 
ADAR2 expression on an array of cellular functions in EC cell lines including a significant decrease of cell prolif-
eration and viability, increased apoptosis rate, and reduced migration capabilities in vitro. Similar to our obser-
vations, silencing of ADARs in breast cancer cell lines led to less cell proliferation and more apoptosis17 and 
overexpression of editing enzymes accelerated growth rate and colony formation in esophageal squamous cell 
carcinoma in vitro36. Taken together, our results strongly suggest, for the first time, that the RNA editing gene 
family, specifically ADAR2, may play an important role promoting EC carcinogenesis.
In conclusion, a global molecular profiling approach using high resolution mass spectrometry has been use-
ful, not only to describe changes in the metabolome and lipidome in human endometrial carcinogenesis and 
EC progression but also led to the discovery of an important alteration of the RNA editing pathway in EC. We 
further demonstrated the role of this pathway in proliferation and viability, apoptosis, and migration of EC cells, 
leading us to conclude that the activation of the RNA editing pathway is an oncogenic process in EC. This study 
opens several avenues for further investigations of ADAR2 as possible target for the development of therapeutic 
approaches for the treatment of EC patients.
Methods
Patients and tissue collection. Discovery and verification phase. A total of 56 women (39 diagnosed with 
EC and 17 non-EC patients) were recruited at Vall Hebron University Hospital (VHUH) in Barcelona, Spain. All 




















 > 50 20 — 20 36 — — 78 29 —
 < 50 — — — —— — — — — —
Collection center
VHUH 20 — 20 7 — — 78 29 —
Lleida — — — 13 — — — — —
Santiago — — — 6 — — — — —
Virgen Rocío — — — 8 — — — — —
MD Anderson — — — 2 — — — — —
Uterine condition
Pre-menopausal — — — — — — — — —
Post-menopausal 20 — 20 36 — — 78 29 —
FIGO stage
IA 10 — — 13 — — 17 7 —
IB 6 — — 10 — — 31 5 —
II 2 — — 5 — — 20 4 —
III 2 — — 8 — — 7 11 —
IV — — — — — — 3 2 —
Histologic grade
G1 4 — — 12 — — 13 0
G2 7 — — 13 — — 33 2
G3 9 — — 11 — — 32 27
Format
TMA — — — 36 — — 78 29 —
Individual slide 20 — 20 — — — — — —
Table 4. Clinical and histological information of patients included in the validation set.
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patients participating signed an informed consent and the study was approved by the Clinical Research Ethics 
Committee (CREC) at the VHUH (approval number: PR_AMI_50–2012). Endometrial tissues were collected at 
the histopathology department of VHUH after the surgical intervention. Each tissue piece (about 5 to 10 mg) was 
placed in a sterile and separate container, properly labeled and stored at −80 °C immediately. A description of the 
clinical and pathological characteristics of the tumors is detailed in Table 1. Inclusion criteria: post-menopausal 
women, > 50 years, no previous treatment for pelvic gynecological cancer, negative for HIV and hepatitis viruses.
Validation phase. Patients split in 3 new cohorts were enrolled in VHUH or in University Hospital Arnau de 
Vilanova of Lleida following the approval of the CREC at each participating institution. Tissue samples were 
embedded in paraffin block for individual slides or tissue microarray (TMA) construction in VHUH. A descrip-
tion of the clinical and pathological characteristics of the tissues is detailed in Table 4.
Tissue metabolomics using Ultra Performance Liquid Chromatography coupled to Quadrupole 
Time-Of-Flight Mass Spectrometry (UPLC-QTOF-MS). Reagents and chemicals: Solvents using chlo-
roform, ACN, water and methanol were purchased from Fisher Optima grade, Fisher Scientific (New Jersey, 
USA). High purity formic acid (99%) was purchased from Thermo-Scientific (Rockford, IL, USA). Ammonium 
formate, debrisoquine and 4-nitrobenzoic acid (4-NBA) were purchased from Sigma- Aldrich (St. Louis, MO, 
USA).
For metabolomics analysis, endometrial tissue samples were prepared following the procedure previously 
described.42 Fresh frozen tissue sections were homogenized on ice using a buffer containing 50% methanol and 
internal standards (1 mg/ml debrisoquine in distilled water, 1 mg/ml of 4-nitrobenzoic acid in methanol, 10 µg/
ml of phosphatidic acid in 50% methanol-water, 0.1 µg/ml of lysophosphatidylcholine in 50% methanol-water). 
Protein precipitation was done by adding a 1:1 ratio of acetonitrile (ACN). Samples were centrifuged, the super-
natant (Supernatant 1) was transferred to a fresh vial and dried under vacuum and the pellet was resuspended in 
prechilled dichloromethane:methanol (3:1). After sonication and centrifugation, the supernatant (Supernatant 2) 
was transferred to a fresh vial and dried under vacuum and the pellet was kept for protein estimation. Supernatant 
Figure 2. ADAR1 and ADAR2 proteins are overexpressed in EC. Panel A. ADAR1 and ADAR2 expression in 
EC tumors (T) compared to the paired control (C) tissues. Relative protein expression of each enzyme is plotted 
in the bar graphs. Panel B. Example of ADAR1 and ADAR2 staining levels in a matched EC tissue with the 
corresponding paired control. Panel C. ADAR1 and ADAR2 expression in EC tissues significantly correlate with 
the tumor grade. Panel D. Example of ADAR1 and ADAR2 staining levels in a set of 3 different EC tumor grades 
slides (grade 1, 2 and 3). Panel E. ADAR1 and ADAR2 levels are significantly increased in NEEC compared to 
EEC tumors. Panel F. Example of ADARs staining in EEC and NEEC tumors.
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1 and Supernatant 2 were finally resuspended in a buffer containing methanol:ACN:water in a ratio 50:25:25 for 
LC-MS analysis. The extraction procedure (from aqueous to semi-polar and lastly non-polar solvent) allows the 
isolation of a wide range of metabolites. In parallel, the pellet was resuspended with RIPA buffer and centrifuged 
in order to quantify the protein amount using Bradford method43. Resuspended pellets (5 µl) were injected onto 
Acquity UPLC CSH 1.7 µm, 2.1 × 100 mm column (Waters Corp.) or in a BEH C18 1.3 µm, 2.1 × 50 mm column. 
The mobile phase gradient consisted of ACN/water (60/40) containing 10 mM ammonium formate and 0.1% 
formic acid (Solvent A) and IPA/ACN (90/10) containing 10 mM ammonium formate and 0.1% formic acid 
(Solvent B). UPLC separation was performed at a flow rate of 0.4 ml/min for 20 min. Two different gradients were 
used in order to analyze the lipidome or the metabolome of the sample. MS data acquisition was performed using 
ESI-QTOF MS within the mass range of 50 to 1200 mass-to-charge ratio (m/z) in positive and negative electro-
spray ionization modes on a SYNAPT G2 Si (Waters Corporation, USA). The capillary voltage used was 3.2 kV 
and a sampling cone voltage of 30 V in negative mode and 20 V in positive mode. The desolvation gas flow was set 
to 750 l/h, and the temperature was set to 350 °C. The cone gas flow was 25 l/h, and the source temperature was 
120 °C. Accurate mass was maintained by infusion of LockSpray interface with Leucine Enkaphalin (556.2771 
[M + H]+ and 554.2615 [M − H]−). Data were acquired in TOF MS centroid mode and also in continuum mode 
for the mass range of 50 to 1200 mass-to-charge ratio (m/z) with MS scanning at a rate of 0.3 seconds. Total 
protein concentration for each sample was used to normalize any inconsistencies that would arise during tissue 
sampling. Subsequently, these data were normalized to internal standard to correct for analytical inconsistencies 
that could potentially occur during MS batch acquisition.
MS data were pre-processed using the XCMS software44. In order to determinate the identification of the 
metabolites based on the mass and charge, the following databases were used: Human Metabolome Database 
(www.hmdb.ca), Madison Metabolomics Consortium Database (mmcd.nmrfam.wisc.edu), LIPID MAPS (www.
lipidmaps.org), KEGG (www.kegg.jp/kegg), and Metlin (metlin.scripps.edu). Multivariate data analysis was per-
formed using Metaboanalyst 3.0 web tool45, 46 and a sub-set of metabolites were verified by tandem mass spec-
trometry (MS/MS) and using Mass Fragments software (Waters Corp.).
Figure 3. Functional assays revealing that ADAR2 presents oncogenic functions in vitro. HEC-1A, Ishikawa 
and RL95-2 EC cell lines were used for the functional assays. Panel A. Proliferation assay showing a significant 
decrease in cell viability (OD 590 nm) in the 3 cell lines when inhibiting ADAR2 expression. Panel B. Apoptosis 
assay showing a significant increase in apoptosis rate when silencing ADAR2. Panel C. Wound healing assay 
indicating a significant decrease in HEC-1A and RL95-2 migration capabilities (% of wound healing) when 
treating cells with siRNA-ADAR2. No significant changes were seen when inhibiting ADAR1.
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Immunohistochemistry. A total of three TMAs were constructed as described previously47. 
Paraffin-embedded TMA or individual sections of the samples were mounted on slides, deparaffined and rehy-
drateted. Antigen retrieval was done during 4 min at 115 °C (pH 6) and subsequently blocked with peroxidase 
(3%) for 5 min and incubated with the primary antibody for 1 h and 30 min at room temperature in a humidified 
chamber. After blocking for 30 min with EnVision secondary antibody (Ref. K5007-100 ml, Agilent; Santa Clara, 
CA, USA) slides were treated with DAB (Ref. K3468, Agilent; Santa Clara, CA, USA) reagent and counterstained 
with hematoxylin for 30 sec. Finally, a dehytratation step and DPX mounting were performed. Pictures were taken 
using the Olympus BX41 microscope (20X). The following antibodies were tested: ADAR1 (Ref. AMAb90535, 
dilution 1:100, Sigma-Aldrich; St. Louis, MO, USA) and ADAR2 (Ref. sc-73409, dilution 1:50, Santa Cruz; 
Heidelberg, Germany, EU). A pathologist evaluated the expression using two criteria: the intensity of staining 
(0, no staining; 1, weak intensity; 2, moderate intensity; 3, high intensity) and the percentage of endometrial epi-
thelial stained cells (0–100). The product of the two scores yielded final values on a sacale ranging from 0 to 300.
Cell lines. The following EC epithelial cell lines were used in this study. HEC-1A (Ref. HTB112, ATCC; 
Manassas, VA, USA) cell line was cultured in McCoys 5 A medium (Ref. 80014020, ThermoFisher; Waltham, 
MA, USA); Ishikawa (Ref. 99040201, Sigma-Aldrich; St. Louis, MO, USA) and RL95-2 (CRL-1671, ATCC; 
Manassas, VA, USA) were cultured in DMEM/F12 (Ref. 11320-033, ThermoFisher; Waltham, MA, USA). Both 
supplemented with penicillin/streptomycin (1%) and fetal bovine serum (10%). Incubated at 37 °C in a 5% CO2 
humidified chamber. Cell lines were morphologically and genetically authenticated and tested for mycoplasma in 
accordance with AACR guides.
Western Blot. Protein extraction from cell lines was performed using RIPA buffer (5 nM EDTA, 150 mM 
NaCl, 1% Triton, 20 nM Tris pH 8 and 1:200 protein inhibitors). After Bradford colorimetric protein quantifica-
tion samples were run on a SDS/PAGE acrylamide gel for 2 h and transferred to a PVDF membrane. Membranes 
were blocked for 1 h with 5% milk and incubated with the primary antibodies described above overnight and 
with the secondary antibodies -Goat anti-rabbit (Ref. P0448, dilution 1:2000, Agilent; Santa Clara, CA, USA) 
and rabbit anti-mouse (Ref. P0260, dilution 1:2000, Agilent; Santa Clara, CA, USA)- for 1 h at room temperature. 
Membranes were developed using Immobilon Immobilon Western Chemiluminiscent (Ref. WBKLS0100, Merck 
Millipore; Billerica, MA, USA). Membranes were finally stained with naphtol blue (Ref. N3393, Sigma-Aldrich; 
St. Louis, MO, USA) to detect all proteins transferred to the membranes in order to normalize the ADAR protein 
bands. The following antibodies were tested: ADAR1 (Ref. AMAb90535, dilution 1:100, Sigma-Aldrich; St. Louis, 
MO, USA) and ADAR2 (Ref. sc-73409, dilution 1:50, Santa Cruz; Heidelberg, Germany, EU).
Immunofluorescence. Cells were fixed for 10 min 96 h after transfection. Cells were blocked for 15 min with 
5% BSA solution in 10 ml of 0.5% PBS-T. They were incubated with the primary antibody for 2 h at room temper-
ature and with the secondary antibody for 45 min at room temperature in a dark chamber. Mounting and DAPI 
staining were performed with ProLong Gold Antifade reagent with DAPI (Ref. P36931, ThermoFisher; Waltham, 
MA, USA). Pictures were taken under the fluorescence microscope Nikon Eclipse TE2000-S. Primary antibodies: 
ADAR1 (Ref. AMAb90535, dilution 1:100, Sigma-Aldrich; St. Louis, MO, USA) and ADAR2 (Ref. sc-73409, dilu-
tion 1:50, Santa Cruz; Heidelberg, Germany, EU). Secondary antibody: Alexa Fluor 488 (Ref. A11017, Labeling 
and detection, ThermoFisher; Waltham, MA, USA).
Figure 4. Project workflow summary.
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Reverse Transfection of siRNAs. Desired number of cells according to the assay (see proliferation, 
apoptosis and wound healing assay sections for the exact number of cells) was seeded using media without 
antibiotic supplementation. Transfection mix was prepared in the following proportion: 25 µl of OptiMEM 
(Ref. 11058021, Invitrogen-ThermoFisher; Waltham, MA, USA), 0.2 µl of lipofectamine (Ref. 11668019, 
Invitrogen-ThermoFisher; Waltham, MA, USA), and 0.375 µl of siRNA (50 nM) and added in a 1:3 (v/v) to 
final volume of the well. After 24 h of transfection, media was changed. Pre-designed siRNAs for ADARs were 
purchased from Sigma-Aldrich: siRNA-ADAR1: SASI Hs01 00115047- GACUAUCUCUUCAAUGUGU; 
siRNA-ADAR2: SASI Hs01 00237747-GAGUGAUCGUGGCCUUGCA; siRNA-ADAR2_B: SASI 
Hs01 00222314- GAGUGAUCGUGGCCUUGCA; siRNA-ADAR2_C: SASI_Hs01_00135204- 
GAGUGAUCGUGGCCUUGCA; siRNA-NC: negative control, BLOCK-it Fluorescent Oligo, for lipid transfec-
tion (Ref. 2013, ThermoFisher; Waltham, MA, USA).
Cell proliferation assay. In order to determine cell proliferation and viability, a total of 4 × 103 cells 
(HEC-1A); 12 × 103 cells (Ishikawa), and 2 × 104 cells (RL95-2) per well were plated in a 96 well plate (6 replicates 
per condition). The cell growth rate was measured after 96 h of transfection. Cells were fixed to the plate with 
glutaraldehide 1% (Ref. G6257, Sigma-Aldrich; St. Louis, MO, USA) for 15 min and stained with Crystal Violet 
(Ref. C3886, Sigma-Aldrich; St. Louis, MO, USA). After 20 min, cells were washed with H2O and Acetic Acid 15% 
(Ref. 0641, ThermoFisher; Waltham, MA, USA) was added. After 10 min shaking plates, they were read at 590 nm. 
Three independent experiments were carried out.
Apoptosis assay. In order to determine cell apoptosis rate, a total of 8 × 104 cells (HEC-1A); 5 × 104 cells 
(Ishikawa), and 2 × 105 cells (RL95-2) per well were seed in a p24 (8 replicates per condition). After 96 h of trans-
fection, cells were stained with Hoechst (1:1000, Ref. H6024, Sigma-Aldrich; St. Louis, MO, USA) and after 24 h 
pictures were taken under the fluorescence microscope Nikon Eclipse TE2000-S. The number of nucleus with 
condensed chromatin and strongly staining of the DNA were quantified as apoptotic cells and divided by the total 
number of nucleus. Three independent experiments were carried out (4 camps per well were counted).
Wound healing assay. To evaluate cell migration capabilities, a total of 8 × 104 cells (HEC-1A); 5 × 104 
cells (Ishikawa), and 2 × 105 cells (RL95-2) per well were seed in a p24 (3 replicates per condition). Wound was 
generated 72 h post-transfection. Pictures were taken every 8 h using an Olympus FSX100 microscope. Wound 
healing area was measured using Image J software at the different time points. Three experiments were carried 
out independently.
All experiments were performed in accordance with the relevant guidelines and regulations.
Statistical analysis. The SPSS statistical package version 23 for Windows® and the GraphPad Prism ver-
sion 6 were used to perform the statistical analyses and ROC analysis. Each value represents the mean of at 
least 3 replicates with the corresponding standard deviation. We analyzed the normality of each data set and we 
used, according to the sample distribution, parametric or no parametric tests. For the IHQ analysis, a Wilcoxon 
signed rank test was used to compare tumors from controls; and a Kruskal-Wallis and Mann-Whitney tests were 
applied when comparing protein expression according to grades and histological subtypes, respectively. For the 
functional analysis, means of the different groups were compared by Kruskal-Wallis followed by Dunn’s multiple 
comparisons test (in case of significance). We considered significant p-values < 0.05. (*p-v < 0.05; **p-v < 0.01; 
***p-v < 0.001; ****p-v: 0.0001).
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